LONDON, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that Jan-Anders Karlsson, CEO of Verona Pharma, will host an investment community conference call detailing the expanded dataset from RPL554 Phase 2b clinical trial in COPD to be presented in an oral presentation at the European Respiratory Society International Congress on Monday, September 17 at 8:30 a.m. CEST.

The investment community call will take place at 8:00 a.m. Eastern Daylight Time (1:00 p.m. British Summer Time) on Tuesday, September 18, 2018. Analysts and Investors may participate in the conference call by dialing the following numbers:

  • 1-877-423-9813 or 1-201-689-8573 for callers in the United States
  • 0 800 756 3429 for callers in the United Kingdom
  • 0 800 182 0040 for callers in Germany

Those interested in listening to the conference call live via the internet may do so by visiting the “Investors” page of Verona Pharma’s website at www.veronapharama.com and clicking on the “Events and presentations” link.

A webcast replay of the conference call (audio) will be available for 30 days on the “Investors” page of Verona Pharma’s website at www.veronapharma.com.

About Verona Pharma plc and RPL554
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma’s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In previous clinical trials, RPL554 has been observed to result in bronchodilator effects when used alone or as an add-on treatment to other COPD bronchodilators. It has shown clinically meaningful and statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators, such as tiotropium (Spiriva®), compared with such bronchodilators administered as a single agent. RPL554 improved FEV1 over four weeks in patients with moderate-to-severe COPD when compared to placebo and improved COPD symptoms and Quality of Life in a Phase 2b multicenter European study performed in 403 patients. In addition, RPL554 has shown anti-inflammatory effects in a standard challenge study with COPD-like inflammation in human subjects. RPL554 has been well tolerated in these studies and has a favorable safety and tolerability profile, having been administered to more than 730 subjects in 12 clinical trials. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (“COPD”), cystic fibrosis (“CF”), and potentially asthma.

For further information, please contact:

Verona Pharma plcTel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officerinfo@veronapharma.com 
  
Stifel Nicolaus Europe Limited (Nominated Adviser
and UK Broker)
Tel: +44 (0) 20 7710 7600
Stewart Wallace / Jonathan Senior / Ben Maddison 
  
FTI Consulting (UK Media and Investor enquiries)Tel: +44 (0)20 3727 1000
Simon Conway / Natalie Garland-Collinsveronapharma@fticonsulting.com 
  
ICR, Inc. (US Media and Investor enquiries) 
James HeinsTel: +1 203-682-8251
James.Heins@icrinc.com
Stephanie CarringtonTel. +1 646-277-1282
Stephanie.Carrington@icrinc.com